RGCC Onco-D-clare

Leading The Way In Early Cancer Detection

RGCC Onco-D-clare is an advanced cancer screening test that detects cancer cells even before symptoms arise. Blending molecular biology and artificial neural networks, we empower individuals with essential insights into their cancer status. Detecting cancer early can ultimately result in improved outcomes and peace of mind for the patients

Sample Type
Whole peripheral blood sample
Sample Size
10ml blood
Family history of cancer/Occupational or habitual hazard exposure/ healthy individuals
Turnaround Time
21 days

How it works?

Onco-D-clare utilizes a blend of molecular biology and artificial neural networks to serve as a cancer screening test. This innovative approach enables the detection of cancer at an early stage, often before symptoms manifest.

How it is done?

Peripheral blood mononuclear cells are extracted from blood samples, and a comprehensive gene expression analysis involving over 90 genes is conducted.
This analysis scrutinizes the expression profile of these genes, which is subsequently employed to classify the sample as either indicative of cancer or representing a healthy state.

Why choose RGCC Onco-D-clare?

The test has undergone clinical validation and demonstrates high accuracy, approximately 82%.

True positive rate (%) = 82.38 +/- 6.55

True negative rate (%) = 81.14+/- 5.42

Molecular biology tests let us look at the entire genetic makeup of something all at once. The qRT-PCR method is both cost-effective and quick. These methods have become more accurate, which is helpful for doctors. Plus, they can check the genetic information using blood sample, which means they don’t always need to do a painful biopsy.


Book an appointment

The first step towards personalized cancer care is scheduling an appointment with us.


30 minutes value packed consultation

Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.


Finding the right tests

We guide you through the process of selecting the most effective tests for your specific cancer.


Personalized results

We deliver precise results that guide treatment decisions and enhance outcomes.

Why clinicians prefer RGCC Onco-D-clare than other similar tests?

Dr. Jervin Lim

“RGCC’s Onco-D-clare test is a breakthrough in early cancer detection. Its accuracy enables timely intervention, improving patient prognosis and overall survival rates. A critical tool in cancer screening and prevention.”

Request a Second Opinion

Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.

Useful information

The Onco-D-clare test can be done for individuals who have a family history of cancer or for individuals who are exposed to carcinogenic products as an occupational hazard or for any individuals who wish for cancer screening.

Onco-D-clare provides individuals with essential information to help them make better-informed decisions about future health and well-being.

Start your personalized cancer journey with us!

Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.

    Frequently Asked Questions

    • Can tests be conducted during ongoing treatment?

      Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.

    • What happens to my blood sample post-testing?

      Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.

    • Is a blood sample sufficient?

      Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.

    • Can the origin of a tumor be determined by the tests?

      Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.

    • What tests are effective in identifying the emergence of secondary tumors?

      RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.

    • How do tests personalize cancer treatment?

      Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.

    • What are CTCs and CSCs?

      Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.

    • Do tests reveal drug response and sensitivity to immunotherapy?

      Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.

    Take the first step towards proactive health management.

    Book your RGCC Onco-D-Clare screening now to identify the potential development of cancer. Empower yourself with valuable insights and start your cancer journey with RGCC Onco-D-Clare!